» Articles » PMID: 29676231

Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential

Overview
Date 2018 Apr 21
PMID 29676231
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative diseases are among the most serious health problems affecting millions of people worldwide. Such diseases are characterized by a progressive degeneration and / or death of neurons in the central nervous system. Currently, there are no therapeutic approaches to cure or even halt the progression of neurodegenerative diseases. During the last two decades, much attention has been paid to the neuroprotective and anti-neurodegenerative activities of compounds isolated from natural products with high efficacy and low toxicity. Accumulating evidence indicates that berberine, an isoquinoline alkaloid isolated from traditional Chinese medicinal herbs, may act as a promising anti-neurodegenerative agent by inhibiting the activity of the most important pathogenic enzymes, ameliorating intracellular oxidative stress, attenuating neuroinflammation, triggering autophagy and protecting neurons against apoptotic cell death. This review attempts to summarize the current state of knowledge regarding the therapeutic potential of berberine against neurodegenerative diseases, with a focus on the molecular mechanisms that underlie its effects on Alzheimer's, Parkinson's and Huntington's diseases.

Citing Articles

Neuroprotective efficacy of berberine and caffeine against rotenone-induced neuroinflammatory and oxidative disturbances associated with Parkinson's disease via inhibiting α-synuclein aggregation and boosting dopamine release.

Waheeb T, Abdulkader M, Ghareeb D, Moustafa M Inflammopharmacology. 2025; .

PMID: 40057928 DOI: 10.1007/s10787-025-01661-w.


Network pharmacology study on the mechanism of berberine in Alzheimer's disease model.

Zhang Y, Lv S, Huang P, Xiao L, Lin N, Huang E NPJ Sci Food. 2025; 9(1):16.

PMID: 39900946 PMC: 11790853. DOI: 10.1038/s41538-025-00378-y.


Revealing the potential therapeutic mechanism of in Alzheimer's disease: a computational biology approach.

Xiang Q, Xiang Y, Liu Y, Chen Y, He Q, Chen T Front Med (Lausanne). 2024; 11:1468561.

PMID: 39606633 PMC: 11598349. DOI: 10.3389/fmed.2024.1468561.


Neuroprotective effect and preparation methods of berberine.

Sunhe Y, Zhang Y, Fu R, Xu D, Tang Y Front Pharmacol. 2024; 15:1429050.

PMID: 39309003 PMC: 11412855. DOI: 10.3389/fphar.2024.1429050.


Prepubertal Repeated Berberine Supplementation Enhances Cerebrocerebellar Functions by Modulating Neurochemical and Behavioural Changes in Wistar Rats.

Owumi S, Chimezie J, Otunla M, Oluwawibe B, Agbarogi H, Anifowose M J Mol Neurosci. 2024; 74(3):72.

PMID: 39042258 DOI: 10.1007/s12031-024-02250-2.


References
1.
Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

2.
Teo K, Ho S . Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. Transl Neurodegener. 2013; 2(1):19. PMC: 3847108. DOI: 10.1186/2047-9158-2-19. View

3.
Lee K, Lo H, Tang W, Hsiao H, Yang P . A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine. Sci Rep. 2014; 4:6394. PMC: 5377252. DOI: 10.1038/srep06394. View

4.
Sontag E, Lee G, Brandt R, Kamibayashi C, Kuret J, White 3rd C . Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem. 1999; 274(36):25490-8. DOI: 10.1074/jbc.274.36.25490. View

5.
Llorens-Martin M, Jurado J, Hernandez F, Avila J . GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7:46. PMC: 4033045. DOI: 10.3389/fnmol.2014.00046. View